302 related articles for article (PubMed ID: 34414850)
1. Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker S; Bittner A; Frick M; Kase J; Hoffmann J; Trenker C; Keller U; Bogner C; Hüttmann A; Dürig J; Janz M; Mathas S; Marks R; Krohn U; Na IK; Bullinger L; Schmitt CA
Leuk Lymphoma; 2022 Jan; 63(1):84-92. PubMed ID: 34414850
[TBL] [Abstract][Full Text] [Related]
2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
4. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
Villacampa G; Dienstmann R; Bosch F; Abrisqueta P
Ann Hematol; 2021 Dec; 100(12):2969-2978. PubMed ID: 34378095
[TBL] [Abstract][Full Text] [Related]
5. R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Pasvolsky O; Rozental A; Raanani P; Gafter-Gvili A; Gurion R
Acta Oncol; 2021 Jun; 60(6):744-749. PubMed ID: 33734921
[TBL] [Abstract][Full Text] [Related]
6. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
[TBL] [Abstract][Full Text] [Related]
8. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
10. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
12. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
13. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
14. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
15. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
16. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ; de Nully Brown P; van der Holt B; D'Amore FA; Koene HR; de Jongh E; Fijnheer R; van Esser JW; Böhmer LH; Pruijt JF; Verhoef GE; Hoogendoorn M; Bilgin MY; Nijland M; van der Burg-de Graauw NC; Oosterveld M; Jie KG; Larsen TS; van der Poel MW; Leijs MB; Silbermann MH; van Marwijk Kooy M; Beeker A; Kersten MJ; Doorduijn JK; Tick LW; Brouwer RE; Lam KH; Burggraaff CN; de Keizer B; Arens AI; de Jong D; Hoekstra OS; Zijlstra-Baalbergen JM
J Clin Oncol; 2020 Oct; 38(29):3377-3387. PubMed ID: 32730183
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ; Papish SW; Venugopal P; Horodner A; Tabatabai A; Hajdenberg J; Park J; Neuwirth R; Mulligan G; Suryanarayan K; Esseltine DL; de Vos S
J Clin Oncol; 2017 Nov; 35(31):3538-3546. PubMed ID: 28862883
[TBL] [Abstract][Full Text] [Related]
19. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
